Discover IXINITY for the treatment of hemophilia B.

What is IXINITY?

IXINITY® [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY to control and prevent bleeding episodes or when you have surgery.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

IXINITY allows you to define your IXperience.

No longer are people with hemophilia B defined by their condition—they’re defined by their abilities and their passions.

IXINITY is a blood-clotting medicine for hemophilia B. IXINITY has an average incremental recovery of 98%.1 Higher recovery may allow lower doses. IXINITY also has a terminal half-life of 24 hours,1 which allows for peak factor levels when you need them.

A different IXperience for people with hemophilia B.

John Taylor’s Hemophilia B Journey

The founder of the Coalition for Hemophilia B and the father of a son with hemophilia B shares his inspiring story of hope.

Aptevo Therapeutics

A company that’s anything but ordinary.

Aptevo Therapeutics is a biotech company focused on novel treatments for people with bleeding disorders and cancer. The scientists at Aptevo discover new ways of meaningfully improving lives by mixing their vast experience with a personal drive to push forward the science of what’s next.

Learn more about Aptevo Therapeutics.

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Seattle, WA: Aptevo BioTherapeutics LLC; December 2018.